ArticleFrontiers in immunology2018
Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 45 citations in OpenAlex.
- Pregabalin enhances the proliferative potential of pancreatic cancer in vitro but not in mice with pancreatic cancer.BMC pharmacology & toxicology · 2026Article
- Preclinical efficacy of dendritic cells loaded with newly identified HPV11 E6-derived CD8NPJ vaccines · 2026Article
- T-Cell Responses and T-Cell-Based Therapy in Acute Myeloid Leukemia.Current medical science · 2025Review
- Gamma delta T cells in cancer therapy: from tumor recognition to novel treatments.Frontiers in medicine · 2024Review
- Effective γδ T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy.Clinical & translational immunology · 2024Review
- Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma.Anticancer research · 2023Review
- Innate lymphoid cells and innate-like T cells in cancer - at the crossroads of innate and adaptive immunity.Nature reviews. Cancer · 2023Review
- Exhausted intratumoral Vδ2Nature immunology · 2023Article
- The intestinal γδ T cells: functions in the gut and in the distant organs.Frontiers in immunology · 2023Review
- IFN-γ and TGF-β, Crucial Players in Immune Responses: A Tribute to Howard Young.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2022Review
- Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.Biomolecules · 2022Review
- Research progress on dendritic cell vaccines in cancer immunotherapy.Experimental hematology & oncology · 2022Review
- Exercise-induced IL-15 acted as a positive prognostic implication and tumor-suppressed role in pan-cancer.Frontiers in pharmacology · 2022Article
- γδ T Cells in the Tumor Microenvironment-Interactions With Other Immune Cells.Frontiers in immunology · 2022Review
- Methylation changes induced by a glycodendropeptide immunotherapy and associated to tolerance in mice.Frontiers in immunology · 2022Article
- Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated byFrontiers in immunology · 2022Article
- Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.Oncogene · 2021Review
- Inflammation and tumor progression: signaling pathways and targeted intervention.Signal transduction and targeted therapy · 2021Article
- Therapeutic potential of interleukin-15 in cancer (Review).Experimental and therapeutic medicine · 2021Review
- The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?Cancer immunology, immunotherapy : CII · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cell (DC) vaccination can be an effective post-remission therapy for acute myeloid leukemia (AML). Yet, current DC vaccines do not encompass the ideal stimulatory triggers for innate gamma delta (γδ) T cell anti-tumor activity. Promoting type 1 cytotoxic γδ T cells in patients with AML is, however, most interesting, considering these unconventional T cells are primed for rapid function and exert meaningful control over AML. In this work, we demonstrate that interleukin (IL)-15 DCs have the capacity to enhance the anti-tumoral functions of γδ T cells. IL-15 DCs of healthy donors and of AML patients in remission induce the upregulation of cytotoxicity-associated and co-stimulatory molecules on the γδ T cell surface, but not of co-inhibitory molecules, incite γδ T cell proliferation and stimulate their interferon-γ production in the presence of blood cancer cells and phosphoantigens. Moreover, the innate cytotoxic capacity of γδ T cells is significantly enhanced upon interaction with IL-15 DCs, both towards leukemic cell lines and allogeneic primary AML blasts. Finally, we address soluble IL-15 secreted by IL-15 DCs as the main mechanism behind the IL-15 DC-mediated γδ T cell activation. These results indicate that the application of IL-15-secreting DC subsets could render DC-based anti-cancer vaccines more effective through, among others, the involvement of γδ T cells in the anti-leukemic immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.